Author: sHq_LoGiNz
20-Year-Old Kokomo Murase from Japan Takes 1st Place in Women’s Snowboard Big Air 24-Year-Old Chloe Kim from Los Angeles Takes World Championship in Women’s Snowboard Halfpipe 20-Year-Old Monster Army Rider Luca Harrington Becomes Men’s Freeski Big Air World Champion, 34-Year-Old Sarah…
31-Year-Old Moreno from Tijuana, Mexico, Earns Unanimous Decision Victory in Main Event 20-Year-Old Raul Rosas Jr. from New Mexico, Beats Vince Morales in Bantamweight Fight MEXICO CITY, Mexico, March 30, 2025 /PRNewswire/ — A special night for MMA in Mexico! Monster Energy congratulates…
RADNOR, Pa., March 30, 2025 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Quantum Computing Inc. (“QCI”) (NASDAQ: QUBT) on behalf of those who purchased or otherwise…
SYDNEY, March 30, 2025 /PRNewswire/ — Li-S Energy (ASX:LIS) (‘Li-S’ or ‘the Company’) has signed a collaboration agreement with Kea Aerospace (Kea) to integrate Li-S’ advanced lithium sulfur battery technology into Kea’s high altitude UAVs targeting multi-month flight times. The…
HONG KONG, March 30, 2025 /PRNewswire/ — CNOOC Limited (the “Company”, SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces today that the Company has made a major oilfield discovery of Huizhou 19-6 in the deep and ultra-deep plays of the South China Sea, which adds…
NEW YORK, March 30, 2025 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering…
VANCOUVER, BC, March 30, 2025 /PRNewswire/ – ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F) (“Else” or the “Company”), announces that further to its news release of March 21, 2025, it is rescheduling the planned business update conference call originally scheduled…
Key Highlights: Global first “immuno + anti-vascular” bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS…
In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years These data were presented at the American College of Cardiology 2025 Scientific Sessions and…